Sale Of Banned Drugs: Patna HC Seeks Bihar Govt Reply

PATNA : The Patna high court on Tuesday sought the state government’s reply on rampant sale of drugs prohibited by the central government and unapproved fixed dose combination (FDC) medicines whose consumption is hazardous to health.

The division bench of Chief Justice Sanjay Karol and Justice S Kumar passed the order while hearing a public interest litigation filed by one Shashi Ranjan Singh, urging the court to direct the authorities concerned to stop sale of prohibited drugs and unapproved FDC medicines.

The petitioner alleged that people sell prohibited drugs in the state by changing their chemical composition slightly.

The petitioner, represented by counsel Shri Prakash Srivastava, also apprised the high court about action taken by authorities in Muzaffarpur in which an assistant drug controller, Shivani, who was earlier posted there, had sent a report to the in-charge state drug controller Ravindra Kumar Sinha, mentioning names of 111 drugs which are under prohibited category as per The Drugs and Cosmetics Act, 1940 but sold at medical stores in Muzaffarpur.

Srivastava also submitted that the assistant drugs controller, in her letter dated June 12, 2021, had also provided names and details of firms manufacturing these drugs and the shops selling them rampantly to common people.

Appearing for the state government, additional advocate general S D Yadav said the petitioner is a mediaperson and has no locus-standi as well as knowledge of the matter. Yadav also vehemently opposed the matter, submitting that it was not a PIL but a writ petition filed with vested interest.

However, the court sought to know from the AAG whether the state government has taken any action on the letter of the assistant drug controller posted in Muzaffarpur. The court told Yadav that the petitioner has raised several other issues too and fixed August 31 as the next date of hearing in the case.

  • Related Posts

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    PharmEasy, the online medical platform emphasizes the importance of early prevention and regular health screenings to reduce the risk of diabetes. By encouraging individuals to undergo timely blood sugar tests,…

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    India’s pharmaceutical exporters have been offered a fresh business opportunity to expand their presence in Saudi Arabia, with Riyadh-based Al Hobail Medical Company seeking Indian manufacturing partners for the registration…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

    From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

    UP expands food, drug testing capacity across all 18 divisions

    UP expands food, drug testing capacity across all 18 divisions

    Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

    Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

    Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi

    Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi